ICML 2017 | Copanlisib produces promising results in relapsed/refractory follicular lymphoma
George Follows, MA, PhD, MRCP, FRCPath from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK discusses the latest early-phase clinical trial data on copanlisib, presented at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Indolent relapsed/refractory lymphoma patients receiving copanlisib as part of the trial tolerated the treatment well, with fewer of the adverse events typically linked to PI3K inhibitors. Dr Follows explains the promising data and the implications of these findings.
Get great new content delivered to your inboxSign up